Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
Ocugen Inc (OCGN) Q3 2026 Earnings Call Highlights: Three Gene Therapy Programs Reach Phase 3 ...
Ocugen Q3 Earnings Call Highlights
Ocugen, Inc. Q3 2026 Earnings Call Summary
Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript
Ocugen (OCGN) Q3 2026 Earnings Call Transcript
Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates
Ocugen: Q3 Earnings Snapshot
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
UPDATE: Ocugen Q3 Adj. EPS $(0.06), Inline, Sales $1.951M Beat $1.098M Estimate
Ocugen Q3 2026 Earnings Call Transcript
Ocugen Q3 EPS $(0.01) Beats $(0.06) Estimate, Sales $1.951M Beat $1.098M Estimate
Ocugen to Participate in Upcoming November Investor and Industry Conferences
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen to Participate in Upcoming Scientific Conferences
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.